以巴马小香猪为动物模型，利用胶带剥离法对自制盐酸特比萘芬成膜给药系统和其市售参比制剂(1％盐酸特比萘芬涂膜剂) 的皮肤药动学进行了初步探索。建立了高效液相色谱法和液质联用法，分别用于测定给药0 ～ 7 d 和7 ～ 14 d 剥离下来的猪皮角质层中的药物浓度。结果显示，自制盐酸特比萘芬成膜给药系统与参比制剂的主要皮肤药动学参数无显著性差异(P>0.05)。自制与参比制剂的cmax 为(14 603.95±1 461.59) 和(14 542.08±1 481.07)ng/cm2， t1/2 为 (75.84±22.35) 和(68.34±3.41)h，AUC0→t 为(920 447.88±166 949.76) 和(901 108.6±141 669.28)ng·cm–2·h ；二者tmax 均为 3 h。自制盐酸特比萘芬成膜给药系统的相对生物利用度为(102.15±15.13)％。
Abstract
Taking BAMA piglet as the experimental animal model, the dermato-pharmacokinetic properties of terbinafine hydrochloride film-forming system and the commercially available product(1％ terbinafine hydrochloride cutaneous solution) were preliminarily investigated by the tape stripping method. An HPLC and a LC/MS were established for determination of drug concentration in the stratum corneum peeled off from the piglet skin on days 0 - 7 and days 7 - 14 after administration, respectively. The results showed that there were no significant differences between the self-made and reference preparations in main pharmacokinetic parameters(P>0.05). The values of cmax, t1/2 and AUC0→t for the self-made and reference preparations were (14 603.95±1 461.59) and (14 542.08±1 481.07)ng/cm2, (75.84±22.35) and (68.34±3.41)h, (920 447.88±166 949.76) and (901 108.6±141 669.28)ng·cm–2·h, respectively. The values of tmax for both preparations were 3 h. The relative bioavailability of the self-made preparation was (102.15±15.13)％.
关键词
盐酸特比萘芬 /
成膜给药系统 /
胶带剥离法 /
皮肤药动学
{{custom_keyword}} /
Key words
terbinafine hydrochloride /
film-forming system /
tape stripping method /
dermato-pharmacokinetics
{{custom_keyword}} /
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] KATHE K, KATHPALIA H．Film forming systems for topical and transdermal drug delivery [J]．Asian J Pharm Sci, 2017, 12(6): 487-497．
[2] 柏佳倩, 马晋隆, 王 健, 等．皮肤局部用聚合物成膜递药系统的研究进展Ⅰ．成膜基质、组成、评价方法、体外释放、透皮渗透试验[J]．中国医药工业杂志, 2020,
51(5): 564-571．
[3] FREDERIKSEN K, GUY R H, PETERSSON K．The potential of polymeric film-forming systems as sustained delivery platforms for topical drugs [J]．Expert Opin Drug Deliv, 2016, 13(3): 349-360．
[4] F R E D E R I K S E N K , G U Y R H , P E T E R S S O N K．Formulation considerations in the design of topical,polymeric film-forming systems for sustained drug delivery to the skin [J]．Eur J Pharm Biopharm, 2015, 91: 9-15．
[5] SAEHENG S, NOSOONGNOEN W, VAROTHAI S, et al．In vitro-invivo correlation study for the dermatopharmacokinetics of terbinafine hydrochloride topical cream [J]．Drug Dev Ind Pharm, 2013, 39(9): 1372-1377．
[6] L U M , X I N G H N , C H E N X , et al．Advance in bioequivalence assessment of topical dermatological products[J]．Asian J Pharm Sci, 2016, 11(6): 700-707．
[7] 李 丽, 杨进波．局部皮肤用药的生物等效性研究进展[J]．中国临床药理学杂志, 2016, 32(24): 2327-2340．
[8] 王 超, 陆 军, 郭春梅．UPLC-MS/MS法检测祛痘类化妆品中盐酸特比萘芬含量 [J]．日用化学品科学, 2020,43(4): 36-39．
[9] BRETERNITZ M, FLACH M, PR?BLER J, et al．Acute barrier disruption by adhesive tapes is influenced by pressure,time and anatomical location: integrity and cohesion assessed by sequential tape stripping; a randopmized, controlled study[J]．Br J Dermatol, 2007, 156(2): 231-240．
[10] GARVIE-COOK H, FREDERIKSEN K, PETERSSON K, et al．Biophysical elucidation of the mechanism of enhanced drug release and topical delivery from polymeric filmforming systems [J]．J Control Release, 2015, 212: 103-112．
[11] DICK I P, SCOTT R C．Pig ear skin as an in-vitro model for human skin permeability [J]．J Pharm Pharmacol, 1992,44(8): 640-645．
[12] KIENZLER J L, QUEILLE-ROUSSEL C, MUGGLESTONE C,et al．Stratum corneum pharmacokinetics of the antifungal drug, terbinafine, in a novel topical formulation, for singledose application in dermatophytoses [J]．Curr Med Res Opin, 2007, 23(6): 1293-1302．
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
PDF(1727 KB)
